News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hemispherx Biopharma (HEB) And GP Pharm Agree To Establish A Manufacturing Operation In Argentina To Serve Latin America Markets And Ancillary Markets


5/21/2014 9:25:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA, May 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced the preliminary stage agreement required to manufacture Ampligen® in Argentina in order to serve Latin American markets should Ampligen® be approved in Argentina. The aforementioned agreement is another important step moving forward in Argentina and South America pursuant to our Sales, Marketing, Distribution and Supply Agreement for Ampligen® with GP Pharm. The agreement is a prerequisite to the company starting the manufacture of stability lots, followed by stability testing, necessary to gain ANMAT's approval to manufacture Ampligen, contingent upon ANMAT approval. The parties are also actively discussing establishing a manufacturing capacity for Alferon® N in Argentina.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES